Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
Published:
Last Updated:
Insiders are using their last open windows to sell shares before they are closed for the earnings reports, and the volume dropped dramatically last week.
Published:
Last Updated:
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
Published:
Last Updated:
These are four top stocks to buy in a sector that has much more value than many on Wall Street. All are rated Buy at Jefferies and have outstanding upside potential.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
Published:
Last Updated:
In this week's top stock picks from Jefferies, three very prominent biotechnology stocks are featured, including one that is a large cap leader.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous report, and short interest increased in all the selected biotech stocks.
Published:
Last Updated:
Celgene shares were trading lower on Friday due to a key management retirement. The problem is that this retirement is just sort out of the blue and was after a rather short tenure.
Published:
Last Updated:
One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is the large cap biotechs.
Published:
Last Updated:
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
Published:
Last Updated:
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
Published:
Last Updated:
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
Published:
Last Updated:
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
Published:
Last Updated: